Applied Therapeutics to Host Virtual Rare Disease Forum
16 Marzo 2021 - 12:00PM
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates against validated molecular targets in indications of
high unmet medical need, today announced it will host a Virtual
Rare Disease Forum on Tuesday, March 23rd, 2021 from 1:00pm to
3:00pm ET. The event will highlight Applied Therapeutics’
development programs in Galactosemia, SORD Deficiency, and
PMM2-CDG. The agenda for the event will include:
-
Update on ACTION-Galactosemia Clinical Development Program
-
Overview of SORD Deficiency, presented by Stephan L. Züchner, MD,
PhD, Professor and Department Chair of Human Genetics at the
University of Miami Miller School of Medicine
-
Update on SORD Deficiency Clinical Development Plans
-
Overview of PMM2-CDG, presented by Joseph Muenzer, MD, PhD,
Professor of Pediatric Genetics and Metabolism at University of
North Carolina Children’s Research Institute
-
Update on PMM2-CDG Clinical Development Program Plans
“We’re excited to host this event to spotlight
our clinical development programs in Galactosemia, SORD and
PMM2-CDG,” said Shoshana Shendelman, PhD, Founder, CEO and
Chair of the Board of Applied Therapeutics. “We believe that AT-007
represents an important advancement for patients with these rare
diseases, and our clinical development programs offer a unique
opportunity to meaningfully impact patients’ lives.”
An audio webcast of the presentation will be
available live. More details will be available at
http://ir.appliedtherapeutics.com leading up to
the event. An archived version of the presentation will be
available following the event.
About Applied TherapeuticsApplied
Therapeutics is a clinical-stage biopharmaceutical company
developing a pipeline of novel drug candidates against validated
molecular targets in indications of high unmet medical need. The
Company’s lead drug candidate, AT-007, is a novel central nervous
system penetrant aldose reductase inhibitor (ARI) for the treatment
of Galactosemia, a rare pediatric metabolic disease. The Company
initiated a pivotal Phase 1/2 clinical trial in June 2019,
read out positive top-line biomarker data in adult Galactosemia
patients in January 2020 and announced full data from the
trial in April 2020. A pediatric Galactosemia study commenced
in June 2020. The Company is also developing AT-001, a novel
potent ARI that is being developed for the treatment of Diabetic
Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The Company
initiated a Phase 3 registrational study in DbCM in September
2019. The preclinical pipeline also includes AT-003, an ARI
designed to cross through the back of the eye when dosed orally,
for the treatment of diabetic retinopathy, as well as novel dual
PI3k inhibitors in preclinical development for orphan oncology
indications.
To learn more, please visit
www.appliedtherapeutics.com and follow the company
on Twitter @Applied_Tx.
Investors:Maeve Conneighton(212) 600-1902
orappliedtherapeutics@argotpartners.com
Media:media@appliedtherapeutics.com
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Lug 2023 a Lug 2024